Episode
BoB@JPM: Brian Hilberdink, Boehringer Ingelheim
- Podcast
- Business Of Biotech
- Published
- Feb 2, 2026
- Duration seconds
- 2675
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/bob-jpm-brian-hilberdink-boehringer-ingelheim/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/bob-jpm-brian-hilberdink-boehringer-ingelheim.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, and following his departure from LEO Pharma (see episode 164). Brian talks about new opportunities in obesity, the benefits of private ownership in funding early science, Boehringer's deal strategy, using AI to improve commercialization efforts, and ...